<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344705</url>
  </required_header>
  <id_info>
    <org_study_id>YMCART201701</org_study_id>
    <nct_id>NCT03344705</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of IM19 Cells</brief_title>
  <official_title>Safety and Efficacy Evaluation of IM19 Chimeric Antigen Receptor-modified T Cells (IM19CAR-T) In CD19+ B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19&#xD;
      Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19&#xD;
      Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies(including&#xD;
      B-cell Acute lymphoblastic Leukemia、B-cell Chronic Lymphocytic Leukemia、Non-Hodgkin's&#xD;
      lymphoma) and Determine the Best Dosage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms,laboratory toxicities,and clinical events that are possibly,likely,or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>2. Overall response rate An objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease assessed by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>IM19 CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IM19 CAR-T</intervention_name>
    <description>All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>IM19</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Two days before cell infusion,all patients will be treated with fludarabine for 3 days</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days</description>
    <arm_group_label>IM19 CART</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with CD19 positive relapsed or refractory B-cell malignancies, including&#xD;
             B-cell Acute Lymphocytic Leukemia(ALL)、B-cell Chronic Lymphocytic&#xD;
             Leukemia(CLL)、Non-Hodgkin's lymphoma(NHL).&#xD;
&#xD;
        1)Patients with ALL:&#xD;
&#xD;
          -  Previously treated with at least two courses of chemotherapy Ⅱ The interval of the&#xD;
             last chemotherapy and disease progression is less than one year.&#xD;
&#xD;
             Ⅲ Not suitable for allogeneic stem cell transplantation. 2)Patients with CLL:&#xD;
&#xD;
          -  Previously treated with at least two courses of chemotherapy&#xD;
&#xD;
             Ⅱ The interval of the last chemotherapy and disease progression is less than two&#xD;
             years.&#xD;
&#xD;
             Ⅲ Not suitable for allogeneic stem cell transplantation conditions or due to&#xD;
             conditions to abandon allogeneic stem cell transplantation.&#xD;
&#xD;
             3) Patients with DLBCL or FL、PMBCL:&#xD;
&#xD;
          -  Patients who relapsed or were refractory after at least two previous treatments.&#xD;
&#xD;
             Ⅱ Patients who relapsed after transplantation. 4)Patients who have relapsed or have&#xD;
             refractory mantle cell lymphoma after at least one treatment.&#xD;
&#xD;
             2.Measurable disease,including minimal residual disease. 3.Gender is not limited, to&#xD;
             be aged 4 to 75 years 4.Expected survival &gt;3 months. 5.Eastern Cooperative Oncology&#xD;
             Group(ECOG) score 0-2. 6.Women of childbearing potential must have a blood pregnancy&#xD;
             test taken and proven negative prior to the treatment. All patients agree to use&#xD;
             reliable methods of contraception during the trial period and until follow-up for the&#xD;
             last time.&#xD;
&#xD;
             7.Absence of symptoms of central nervous system(CNS) leukemia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have been treated with chemotherapy or radiotherapy within 2 weeks before&#xD;
             blood collection.&#xD;
&#xD;
          2. Patients have GVHD, which needs treatment with immunosuppressive agents,or patients&#xD;
             with autoimmune diseases.&#xD;
&#xD;
          3. Patient who have been treated with systemic steroid medication within two weeks of&#xD;
             blood collection（Except for the recent or current use of inhaled steroids）.&#xD;
&#xD;
          4. Patient who have been treated with stimulation of bone marrow hematopoietic cells&#xD;
             generated drugs(Such as Recombinant Human Granulocyte Colony-stimulating Factor&#xD;
             Injection) within 2 weeks before the blood collection period to use .&#xD;
&#xD;
          5. The number of T cells in peripheral blood is lower than 2×10^8/L.&#xD;
&#xD;
          6. Previously treatment with any gene therapy products.&#xD;
&#xD;
          7. History of epilepsy or other CNS disease.&#xD;
&#xD;
          8. New York Heart Association(NYHA) grade≥Ⅲ.&#xD;
&#xD;
          9. Creatinine&gt; 1.5×normal value，Alanine transaminase(ALT) /Aspartate&#xD;
             aminotransferase(AST)&gt;3×normal value，Bilirubin &gt;2×normal value.&#xD;
&#xD;
         10. Degree of myeloproliferation： Ⅳ-V&#xD;
&#xD;
         11. Active hepatitis B , hepatitis C or HIV infection and cytomegalovirus infection&#xD;
             ,Epstein-Barr virus infection or any other uncontrolled active infection.&#xD;
&#xD;
         12. Pregnancy or breast-feeding women.&#xD;
&#xD;
         13. Any uncontrolled medical disorders that the researchers considered are not suitable to&#xD;
             participate the clinical trial.&#xD;
&#xD;
         14. Any situation that would increase dangerousness of subjects or disturb the outcome of&#xD;
             the clinical study according to the researcher's evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongmei Jing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin-an Lu, Dr</last_name>
    <phone>86-189-1157-6946</phone>
    <email>luxinan@immunochina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinan Lu, Dr</last_name>
      <phone>86-189-1157-6946</phone>
      <email>luxian@immunochina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

